|1.||Moral, M A: 3 articles (12/2010 - 11/2009)|
|2.||Tomillero, A: 3 articles (12/2010 - 11/2009)|
|3.||Kawamori, R: 2 articles (09/2009 - 09/2009)|
|4.||Iwamoto, Y: 2 articles (09/2009 - 09/2009)|
|5.||Iwasaki, M: 2 articles (09/2009 - 09/2009)|
|6.||Kadowaki, T: 2 articles (09/2009 - 09/2009)|
|7.||Taxis, Katja: 1 article (06/2015)|
|8.||Berhe, Derbew Fikadu: 1 article (06/2015)|
|9.||Haaijer-Ruskamp, Flora M: 1 article (06/2015)|
|10.||Juhlin, Kristina: 1 article (06/2015)|
|1.||Type 2 Diabetes Mellitus (MODY)
09/01/2009 - "Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus."
09/01/2009 - "To evaluate the safety and efficacy of insulin glulisine (glulisine) with and without oral antidiabetic drugs (OAD; sulphonylurea or sulphonylurea + biguanide) relative to that of OAD alone in Japanese and Korean patients with inadequately controlled type 2 diabetes mellitus (T2DM). "
04/01/2005 - "Clinical trials have demonstrated that insulin glulisine elicits a greater reduction in glycosylated haemoglobin at end point than RHI, in both type 1 and 2 diabetes mellitus. "
01/01/2010 - "The role of insulin glulisine to improve glycemic control in children with diabetes mellitus."
05/29/2009 - "Insulin glulisine: a review of its use in the management of diabetes mellitus."
03/01/2009 - "Insulin glulisine: aspects of basal/bolus therapy for optimized treatment of diabetes mellitus."
05/29/2009 - "Insulin glulisine (Apidra) is a human insulin analogue approved for the improvement of glycaemic control in adults, adolescents and children with diabetes mellitus. "
07/01/2013 - "The objective of this study was to determine if insulin glulisine (Apidra), another rapid-acting insulin analog, would be superior in controlling postprandial hyperglycemia in children with T1DM. "
03/01/2015 - "Insulin glulisine effectively suppressed postprandial hyperglycemia, whereas regular insulin caused a prolonged hypoglycemic action. "
06/01/2006 - "Unexplained hyperglycemia occurred in six insulin glulisine-treated patients and twelve insulin as part-treated patients. "
10/01/2003 - "Aventis Pharma (formerly Hoechst Marion Roussel) is developing insulin glulisine, a fast-acting insulin analog, for the potential treatment of hyperglycemia in both type 1 and 2 diabetes. "
|5.||Hypoglycemia (Reactive Hypoglycemia)
11/01/2011 - "Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody--a case report."
01/01/2009 - "The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA(1c) seem similar among the rapid-acting insulin analogs, including insulin glulisine. "
07/01/2005 - "Insulin glulisine effectively controls postprandial glucose excursions in both type 1 and type 2 diabetic patients without increasing the risk of hypoglycemia. "
01/01/2015 - "This noninterventional, 8-month, prospective, multicenter study evaluated parameters of glucose control, occurrence of adverse events (eg, hypoglycemia), and acceptance of devices in daily clinical practice routine after 12 and 24 weeks of intensifying insulin therapy to a BBT regimen starting from either preexisting BOT with insulin glargine (pre-BOT) or preexisting SIT with ≥3 daily injections of insulin glulisine (pre-SIT). "
07/01/2012 - "Search terms included "animal insulin," "synthetic insulin," "regular human insulin," "insulin lispro," "insulin aspart," "insulin glulisine," "insulin glargine," "insulin detemir," "insulin degludec," "biphasic human insulin," "insulin premixes," "ultra-long acting," "oral insulin," and "inhaled insulin." While the discovery of animal insulin significantly decreased mortality rates from diabetes, issues with availability and large variability between batches led to difficulty in determining proper doses and, subsequently, challenges in achieving glycemic control and avoiding hypoglycemia. "
|1.||Hypoglycemic Agents (Hypoglycemics)
|3.||glargine (insulin glargine)
|5.||insulin LISPRO (Humalog)
|9.||Blood Glucose (Blood Sugar)